WO2024246863 - CHEMICAL COMPOUNDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/246863
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055354
International Filing Date
31.05.2024
Title **
[English]
CHEMICAL COMPOUNDS AND USES THEREOF
[French]
COMPOSÉS CHIMIQUES ET LEURS UTILISATIONS
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
IDEAYA BIOSCIENCES, INC.
Inventors
DEMARTINO, Michael P.
BRNARDIC, Edward
PHELAN, James P.
CAMPBELL, Kira A.
JONES, Brian T.
TAYGERLY, Joshua P.G.
RYAN, Jonathon S.
SEVERANCE, Daniel L.
Priority Data
63/505,508
01.06.2023
US
63/583,600
19.09.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2558 | |
| EPO | Filing, Examination, Granting | 10397 | |
| Japan | Filing, Examination, Granting | 2211 | |
| South Korea | Filing, Examination, Granting | 2106 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,612
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are certain chemical compounds that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are therefore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.[French]
L'invention concerne certains composés chimiques qui inhibent l'activité de l'enzyme hélicase dépendante de l'ATP du syndrome de Werner (WRN), en particulier l'activité du domaine de l'hélicase WRN et qui sont par conséquent utiles dans le traitement de cancers pouvant être traités par inhibition de WRN, y compris des cancers caractérisés par une instabilité des microsatellites (MSI) et/ou un système de réparation de mésappariement d'ADN défectueux (dMMR). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés d'utilisation de tels composés, et des procédés de préparation de ceux-ci.